Table 2

Mean baseline and post-treatment SF-36 PCS and MCS scores and SF-6D scores across trials

Weeks 1–12Weeks 13–24 (ETN 25 mg)*
ETN + MTXMTXETNPlaceboETN 25 mgETN 50 mgPlaceboETN 25 mgETN 50 mgPlacebo
 Mean change13.810.
 p Value0.003NS0.001NS<0.0001<0.0001NS
 Mean change6.
 p ValueNSNS0.040NS<0.0001<0.0001NS
 Mean change0.1280.1210.1050.0180.0650.0840.0110.0660.0830.077
 p Value<0.0001<0.0001<0.00010.079<0.0001<0.00010.285
  • * All patients received etanercept 25 mg twice a week during weeks 13–24, column headers represent original treatment assignment, p values are comparisons with week 12 values.

  • Changes were greater than or equal to the minimal clinically important difference (MCID).

  • p Value for change from baseline.

  • ETN, etanercept; MCS, mental component summary; MTX, methotrexate; NS, not significant; PCS, physical component summary; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SF-36, short form 36; SF-6D, health utility score based on mean scores across all eight domains of the SF-36.